3/16
09:00 am
ird
Opus Genetics (IRD) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
Low
Report
Opus Genetics (IRD) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
3/12
08:44 am
ird
Opus Genetics (IRD) had its price target raised by Wedbush from $8.00 to $10.00. They now have an "outperform" rating on the stock.
Medium
Report
Opus Genetics (IRD) had its price target raised by Wedbush from $8.00 to $10.00. They now have an "outperform" rating on the stock.
3/12
08:44 am
ird
Opus Genetics (IRD) had its price target raised by Chardan Capital from $9.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Opus Genetics (IRD) had its price target raised by Chardan Capital from $9.00 to $11.00. They now have a "buy" rating on the stock.
3/11
02:15 pm
ird
Opus Genetics (IRD) was given a new $9.00 price target by Craig Hallum. They now have a "buy" rating on the stock.
Low
Report
Opus Genetics (IRD) was given a new $9.00 price target by Craig Hallum. They now have a "buy" rating on the stock.
3/10
10:44 pm
ird
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
3/10
07:37 am
ird
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update [Yahoo! Finance]
Low
Report
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update [Yahoo! Finance]
3/10
07:00 am
ird
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
Low
Report
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
3/3
08:13 am
ird
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 [Yahoo! Finance]
Neutral
Report
Opus Genetics to Present at Upcoming Investor Conferences in March 2026 [Yahoo! Finance]
3/3
08:00 am
ird
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
Neutral
Report
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
3/2
08:03 am
ird
Opus Genetics (IRD) had its price target raised by BTIG Research from $7.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Opus Genetics (IRD) had its price target raised by BTIG Research from $7.00 to $12.00. They now have a "buy" rating on the stock.
3/1
01:10 am
ird
Medium
Report
2/27
10:40 am
ird
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting [Yahoo! Finance]
High
Report
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting [Yahoo! Finance]
2/27
10:10 am
ird
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
High
Report
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
2/25
07:18 am
ird
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]
Medium
Report
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]
2/25
06:59 am
ird
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Medium
Report
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
2/22
09:40 pm
ird
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
Neutral
Report
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
2/13
02:48 pm
ird
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]
Low
Report
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]
2/13
07:30 am
ird
Opus Genetics Announces $25 Million Private Placement
Medium
Report
Opus Genetics Announces $25 Million Private Placement
2/13
06:29 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
2/2
08:00 am
ird
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Low
Report
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
1/28
08:04 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
1/27
07:00 am
ird
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Low
Report
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
1/21
06:19 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
1/20
07:01 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
1/8
07:00 am
ird
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
Medium
Report
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts